TCZ+GN TR

Translational research for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030200192

Enrollment

Registered

2020-11-10

Start date

2019-05-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer Pancreatic ductal adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Partipants for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer 2. Tumor tissue from the patient was available 3. Written informed consent for participation in the study is obtained at the discretion of the patient.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1. Suppresion of IL-6 signaling using a decrease of intratumoral pSTAT3 expression 2. Suppresion of desmoplasia using a decrease of intratumoral alppha-SMA expression 3. Change of tumor-infiltrating lymphocyte	—

Contacts

Public ContactShucihi Mitsunaga

National Cancer Center Hospital East

smitsuna@east.ncc.go.jp+81-4-7133-1111

Outcome results